Adding tafasitamab and lenalidomide to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) may offer a meaningful advance for patients with newly diagnosed high-risk diffuse ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

ADC Therapeutics ADCT shares plunged 53.4% in after-hours trading on Wednesday despite the company reporting positive ...

In early June 2026, ADC Therapeutics reported topline Phase 3 LOTIS-5 data showing ZYNLONTA plus rituximab improved progression-free survival and response depth versus R-GemOx in relapsed or ...

In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...

In late May 2026, Incyte reported that its pivotal Phase 3 frontMIND trial showed tafasitamab (Monjuvi/Minjuvi) plus lenalidomide and R-CHOP significantly improved progression-free survival versus ...

ADC Therapeutics SA ADCT stock is trading lower on Thursday after the company indicated that LOTIS-5 showed elevated serious ...